Omapatrilat

Chemical compound
  • None
Legal statusLegal status
  • Development terminated
Identifiers
  • (4S,7S,10aS)-Octahydro-4-[(S)-α-mercaptohydrocinnamamido]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
CAS Number
  • 167305-00-2 checkY
PubChem CID
  • 656629
ChemSpider
  • 570983 ☒N
UNII
  • 36NLI90E7T
KEGG
  • D01970 ☒N
ChEMBL
  • ChEMBL289556 ☒N
CompTox Dashboard (EPA)
  • DTXSID80168273 Edit this at Wikidata
Chemical and physical dataFormulaC19H24N2O4S2Molar mass408.53 g·mol−13D model (JSmol)
  • Interactive image
  • c1ccc(cc1)C[C@@H](C(=O)N[C@H]2CCS[C@H]3CCC[C@H](N3C2=O)C(=O)O)S
InChI
  • InChI=1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13-,14-,15-,16-/m0/s1 ☒N
  • Key:LVRLSYPNFFBYCZ-VGWMRTNUSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Omapatrilat (INN,[1] proposed trade name Vanlev) is an experimental antihypertensive agent that was never marketed.[2] It inhibits both neprilysin (neutral endopeptidase, NEP) and angiotensin-converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling.

It was discovered and developed by Bristol-Myers Squibb but failed in clinical trials as a potential treatment for congestive heart failure due to safety concerns about its causing angioedema.[3]

Omapatrilat angioedema was attributed to its dual mechanism of action, inhibiting both angiotensin-converting enzyme (ACE), and neprilysin (neutral endopeptidase), both of these enzymes are responsible for the metabolism of bradykinin which causes vasodilation, angioedema, and airway obstruction.

See also

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 40" (PDF). World Health Organization. p. 190. Retrieved 2 March 2017.
  2. ^ "Omapatrilat". Adis Insight. Springer Nature Switzerland AG.
  3. ^ Venugopal J (2 March 2005). "Pharmacological Modulation of the Natriuretic Peptide System". Expert Opinion on Therapeutic Patents. 13 (9): 1389–1409. doi:10.1517/13543776.13.9.1389. S2CID 85007768.

Further reading

  • Liao WC, Vesterqvist O, Delaney C, Jemal M, Ferreira I, Ford N, et al. (October 2003). "Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects". British Journal of Clinical Pharmacology. 56 (4): 395–406. doi:10.1046/j.1365-2125.2003.01888.x. PMC 1884361. PMID 12968984.
  • v
  • t
  • e
ACE inhibitors
("-pril")AIIRAs
("-sartan")Renin inhibitors
("-kiren")Dual ACE/NEP inhibitors
Neprilysin inhibitors
  • v
  • t
  • e
ATRTooltip Angiotensin receptor
Combinations:
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e